Phase 2 N=1,024 Randomized Single-blind Prevention

A Network & Dyad HIV Prevention Intervention for IDU's - 1

HIV · Hepatitis

Bottom Line

View on ClinicalTrials.gov: NCT00218335 ↗

Enrolled (actual)

1,024

Serious AEs

0.0%

Results posted

Apr 2013

Primary outcome: Primary: Any Sex Risk — 48; 62; 119; 179 participants

Study Design & Population

Study type: Interventional
Phase: Phase 2
Interventions: Intervention Condition (Behavioral); Control Condition (Behavioral)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: Johns Hopkins Bloomberg School of Public Health
Primary completion: May 2008

Outcome Measures

Outcome	Result	p-value
PRIMARY Any Sex Risk	48; 62; 119; 179	—
PRIMARY Talked About HIV-related Topics With Drug Buddies (in the Past Month)	60; 46; 98; 105	—
PRIMARY Showed a Needleless Syringe to Drug Buddies	84; 22; 37; 67	—
PRIMARY Talked About Responding to Overdose to Drug Buddies	2; 21	—
PRIMARY Any Injection Risk (Monthly Versus Never)	12; 25; 63; 46	—
PRIMARY Number of Needle or Cooker Sharers (2 or More Versus None)	5; 17; 45; 23	—
PRIMARY Talked About HIV-related Topics With Drug Buddies (in the Past Month)	60; 46; 98; 105	—
PRIMARY Showed a Needleless Syringe to Drug Buddies	84; 22; 37; 67	—
PRIMARY Any Injection Risk (Monthly Versus Never)	12; 25; 63; 46	—
PRIMARY Shared Cooker When Preparing Drugs	18; 36; 84; 66	—
PRIMARY Number of Needle or Cooker Sharers (2 or More Versus None)	5; 17; 45; 23	—
PRIMARY Injecting Drugs	35; 58; 143; 108	—
PRIMARY Talked About HIV-related Topics With Drug Buddies (in Past Month)	44; 35; 96; 106	—
PRIMARY Showed a Needleless Syringe to Drug Buddies	84; 22; 37; 67	—
PRIMARY Talked About Hepatitis to Drug Buddies	51; 29	—

Summary

The purpose of this study is to evaluate a peer-based HIV prevention intervention that targets active injection drug users and their drug and sex partners.

Eligibility Criteria

Inclusion Criteria

(i)Self reported injection drug use within the prior 6 months; (ii)Willingness to invite a risk network member into the study and to talk about HIV prevention; (iii)Age 18 or older

Exclusion Criteria

Not concurrently enrolled in another HIV prevention intervention

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00218335). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.